SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 1.180-0.8%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: hoffy who wrote (1288)11/7/1998 1:05:00 PM
From: Gemini  Read Replies (3) of 3576
 
hoffy,

You don't have a clue as to what you're talking about. Get
your "short" hands on today's Investor's Business Daily and
read its excellent write-up starting from Page 1. Some of
IBD's principal points are:

-- Geron has secured over $44 million in research funding
from Pharmacia & Upjohn, Roche Holdings, and Kyowa Hakko.

-- In 1997, GERN lost $9.6 million or 93 cents a share.
For the first six months of this year, it lost 39 cents.

-- CEO Ron Eastman hopes to secure more partnerships, which
he says could turn the company profitable. Geron has
already demonstrated that it can form partnerships.

-- "This is a very big deal" said Lana Skirboll, director of
the Office of Science Policy at the National Institutes of
Health. "The potential of this research is remarkable."

This stock's upside is far greater than the downside risk IMHO.
Sure you can trade it day-to-day, but most common sense
investors will be in this one for the long haul to realize the
largest returns.

Good luck, Allan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News